Her Majesty's Government what is their assessment of the benefits and costs to the UK of membership of the European Medicines Agency.
18 July 2017
We recognise the important role that the European Medicines Agency plays in the protection of human and animal health.
In the negotiations, the Government will discuss with the European Union and Member States how best to continue cooperation in the field of medicines regulation in the best interests of both the United Kingdom and the EU. As my Rt. hon. Friends the Secretaries of State for Health and Business said in their 4 July letter in the Financial Times, the UK is fully committed to continuing the close working relationship with our European partners. Our aim is to ensure that patients in the UK and across the EU continue to be able to access the best and most innovative medicines and be assured that their safety is protected through the strongest regulatory framework and sharing of data.
I underlined this message, in particular the value the UK places on ongoing co-operation, at the BioIndustry Association and Medicines and Healthcare products Regulatory Agency conference on 14 July.